Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (CovovaxTM) given as a third (booster) dose to individuals primed with different primary vaccine regimens. Methods: A third dose was administered to individuals with an interval range of 3-10 months after the second dose. The four groups were classified according to their primary vaccine regimens, including two-dose BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, neutralizing activity, and the T-cell responses. Results: Overall, 210 individuals were enrolled and boosted with the CovovaxTM vaccine. The reactogenicity was mild to moderate. Most participants elicited a high level of binding and neutralizing antibody against Wild-type and Omicron variants after the booster dose. In participants who were antinucleocapsid immunoglobulin G-negative from all groups, a booster dose could elicit neutralizing activity to Wild-type and Omicron variants by more than 95% and 70% inhibition at 28 days, respectively. The CovovaxTM vaccine could elicit a cell-mediated immune response. Conclusion: The protein subunit vaccine (CovovaxTM) can be proposed as a booster dose after two different priming dose regimens. It has strong immunogenicity and good safety profiles..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:126 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 126(2023), Seite 64-72 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sitthichai Kanokudom [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Booster dose |
|---|
| doi: |
10.1016/j.ijid.2022.11.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ020801750 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ020801750 | ||
| 003 | DE-627 | ||
| 005 | 20230502100155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2022.11.022 |2 doi | |
| 035 | |a (DE-627)DOAJ020801750 | ||
| 035 | |a (DE-599)DOAJ40115bccb3964fff949c415a57ef1d8c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Sitthichai Kanokudom |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: To report the safety and immunogenicity profile of a protein subunit vaccine (CovovaxTM) given as a third (booster) dose to individuals primed with different primary vaccine regimens. Methods: A third dose was administered to individuals with an interval range of 3-10 months after the second dose. The four groups were classified according to their primary vaccine regimens, including two-dose BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, neutralizing activity, and the T-cell responses. Results: Overall, 210 individuals were enrolled and boosted with the CovovaxTM vaccine. The reactogenicity was mild to moderate. Most participants elicited a high level of binding and neutralizing antibody against Wild-type and Omicron variants after the booster dose. In participants who were antinucleocapsid immunoglobulin G-negative from all groups, a booster dose could elicit neutralizing activity to Wild-type and Omicron variants by more than 95% and 70% inhibition at 28 days, respectively. The CovovaxTM vaccine could elicit a cell-mediated immune response. Conclusion: The protein subunit vaccine (CovovaxTM) can be proposed as a booster dose after two different priming dose regimens. It has strong immunogenicity and good safety profiles. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a Side effect | |
| 650 | 4 | |a CovovaxTM | |
| 650 | 4 | |a Novavax | |
| 650 | 4 | |a Booster dose | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Jira Chansaenroj |e verfasserin |4 aut | |
| 700 | 0 | |a Nungruthai Suntronwong |e verfasserin |4 aut | |
| 700 | 0 | |a Suvichada Assawakosri |e verfasserin |4 aut | |
| 700 | 0 | |a Ritthideach Yorsaeng |e verfasserin |4 aut | |
| 700 | 0 | |a Pornjarim Nilyanimit |e verfasserin |4 aut | |
| 700 | 0 | |a Ratchadawan Aeemjinda |e verfasserin |4 aut | |
| 700 | 0 | |a Nongkanok Khanarat |e verfasserin |4 aut | |
| 700 | 0 | |a Preeyaporn Vichaiwattana |e verfasserin |4 aut | |
| 700 | 0 | |a Sirapa Klinfueng |e verfasserin |4 aut | |
| 700 | 0 | |a Thanunrat Thongmee |e verfasserin |4 aut | |
| 700 | 0 | |a Apirat Katanyutanon |e verfasserin |4 aut | |
| 700 | 0 | |a Wichai Thanasopon |e verfasserin |4 aut | |
| 700 | 0 | |a Jirawan Arayapong |e verfasserin |4 aut | |
| 700 | 0 | |a Withak Withaksabut |e verfasserin |4 aut | |
| 700 | 0 | |a Donchida Srimuan |e verfasserin |4 aut | |
| 700 | 0 | |a Thaksaporn Thatsanatorn |e verfasserin |4 aut | |
| 700 | 0 | |a Natthinee Sudhinaraset |e verfasserin |4 aut | |
| 700 | 0 | |a Nasamon Wanlapakorn |e verfasserin |4 aut | |
| 700 | 0 | |a Sittisak Honsawek |e verfasserin |4 aut | |
| 700 | 0 | |a Yong Poovorawan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 126(2023), Seite 64-72 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:126 |g year:2023 |g pages:64-72 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2022.11.022 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/40115bccb3964fff949c415a57ef1d8c |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971222006142 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 126 |j 2023 |h 64-72 | ||